Edition:
United States

Celgene Corp (CELG.O)

CELG.O on Nasdaq

95.24USD
24 May 2019
Change (% chg)

$-0.39 (-0.41%)
Prev Close
$95.63
Open
$95.79
Day's High
$96.02
Day's Low
$95.19
Volume
3,464,916
Avg. Vol
8,714,287
52-wk High
$97.07
52-wk Low
$58.59

Latest Key Developments (Source: Significant Developments)

Bristol-Myers Squibb Says Requisite Number Of Consents Received To Adopt Proposed Amendments With Respect To All Outstanding Notes Of Celgene Corporation
Wednesday, 1 May 2019 09:06pm EDT 

May 1 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB COMPANY ANNOUNCES RESULTS OF EARLY PARTICIPATION IN EXCHANGE OFFERS AND CONSENT SOLICITATIONS FOR CELGENE CORPORATION NOTES.BRISTOL-MYERS SQUIBB - REQUISITE NUMBER OF CONSENTS RECEIVED TO ADOPT PROPOSED AMENDMENTS WITH RESPECT TO ALL OUTSTANDING NOTES OF CELGENE CORPORATION.  Full Article

Celgene Q1 Earnings Per Share $2.14
Thursday, 25 Apr 2019 04:30pm EDT 

April 25 (Reuters) - Celgene Corp ::CELGENE REPORTS FIRST QUARTER 2019 OPERATING AND FINANCIAL RESULTS.Q1 REVENUE $4.025 BILLION VERSUS REFINITIV IBES ESTIMATE OF $4.01 BILLION.Q1 EARNINGS PER SHARE $2.14.Q1 EARNINGS PER SHARE ESTIMATE $2.43 -- REFINITIV IBES DATA.REAFFIRMING 2019 GUIDANCE AND 2020 FINANCIAL TARGETS.REVLIMID SALES FOR Q1 WERE $2,577 MILLION, AN INCREASE OF 15 PERCENT YEAR-OVER-YEAR.OTEZLA SALES FOR Q1 WERE $389 MILLION, A 10 PERCENT INCREASE YEAR-OVER-YEAR.ACQUISITION BY BRISTOL-MYERS SQUIBB EXPECTED TO CLOSE IN Q3 OF 2019.QTRLY ADJUSTED. EARNINGS PER SHARE $2.55.FY2019 EARNINGS PER SHARE VIEW $10.70, REVENUE VIEW $17.11 BILLION -- REFINITIV IBES DATA.  Full Article

Bristol-Myers Squibb Reports First Quarter Financial Results
Thursday, 25 Apr 2019 06:59am EDT 

April 25 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB REPORTS FIRST QUARTER FINANCIAL RESULTS.Q1 NON-GAAP EARNINGS PER SHARE $1.10.Q1 GAAP EARNINGS PER SHARE $1.04.Q1 REVENUE $5.9 BILLION VERSUS REFINITIV IBES ESTIMATE OF $5.75 BILLION.Q1 EARNINGS PER SHARE ESTIMATE $1.09 -- REFINITIV IBES DATA.RAISES FY 2019 NON-GAAP EARNINGS PER SHARE VIEW TO $4.10 TO $4.20.RAISES FY 2019 GAAP EARNINGS PER SHARE VIEW TO $3.84 TO $3.94.REAFFIRMS NON-GAAP EPS GUIDANCE RANGE OF $4.10-$4.20.QTRLY U.S. REVENUES INCREASED 24% TO $3.4 BILLION IN QUARTER COMPARED TO SAME PERIOD A YEAR AGO.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $10.0 BILLION, WITH A NET CASH POSITION OF $4.0 BILLION, AS OF MARCH 31, 2019.RESULTS FOR Q1 OF 2019 INCLUDE $187 MILLION OF CELGENE-RELATED ACQUISITION AND INTEGRATION EXPENSES.COMPANY TODAY ANNOUNCED TOPLINE RESULTS FROM PHASE 2 CHECKMATE -714 TRIAL EVALUATING OPDIVO VERSUS OPDIVO PLUS YERVOY.STUDY DID NOT MEET ITS PRIMARY ENDPOINTS.QTRLY OPDIVO WORLWIDE REVENUE $1,801 MILLION VERSUS $1,511 MILLION.SEES 2019 WORLDWIDE REVENUES INCREASING IN MID-SINGLE DIGITS.QTRLY ELIQUIS WORLDWIDE REVENUE $1,925 MILLION VERSUS $1,506 MILLION.SEES 2019 GROSS MARGIN AS A PERCENTAGE OF REVENUE TO BE APPROXIMATELY 70% FOR BOTH GAAP AND NON-GAAP.QTRLY SPRYCEL WORLDWIDE REVENUE $459 MILLION VERSUS $438 MILLION.BRISTOL-MYERS SQUIBB - SALE OF UPSA CONSUMER HEALTH BUSINESS TO TAISHO PHARMACEUTICAL FOR $1.6 BILLION IS ANTICIPATED TO BE COMPLETED IN JULY 2019.  Full Article

Celgene Corp And Acceleron Pharma Announce Submission Of Luspatercept Biologics License Application To U.S. FDA
Friday, 5 Apr 2019 09:28am EDT 

April 5 (Reuters) - Celgene Corp ::CELGENE CORPORATION AND ACCELERON PHARMA ANNOUNCE SUBMISSION OF LUSPATERCEPT BIOLOGICS LICENSE APPLICATION TO U.S. FDA.CELGENE CORP - EMA MARKETING APPLICATION FOR BOTH INDICATIONS PLANNED FOR Q2:19.CELGENE CORP - BLA SUBMISSION INCLUDES BOTH MYELODYSPLASTIC SYNDROMES AND BETA-THALASSEMIA INDICATIONS.CELGENE CORP - COMPANIES ALSO PLAN TO SUBMIT A MARKETING APPLICATION TO EUROPEAN MEDICINES AGENCY IN Q2 OF 2019..  Full Article

Bristol-Myers Squibb And Celgene Received Request For Additional Information And Documentary Materials From FTC
Tuesday, 26 Mar 2019 07:44am EDT 

March 26 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB - CO, CELGENE RECEIVED REQUEST FOR ADDITIONAL INFORMATION AND DOCUMENTARY MATERIALS FROM FTC.BRISTOL-MYERS SQUIBB - PARTIES UNDERSTAND THAT FTC’S REVIEW IS FOCUSED ON MARKETED AND PIPELINE PRODUCTS FOR THE TREATMENT OF PSORIASIS..BRISTOL-MYERS SQUIBB - REQUEST FOR ADDITIONAL INFORMATION FROM FTC IN CONNECTION WITH THE FTC’S REVIEW OF THE MERGER.BRISTOL-MYERS SQUIBB - BOTH PARTIES CONTINUE TO EXPECT THAT THE MERGER WILL BE CONSUMMATED IN THE THIRD QUARTER OF 2019.BRISTOL-MYERS SQUIBB CO - PARTIES WILL CONTINUE TO WORK COOPERATIVELY WITH THE FTC.  Full Article

Bristol-Myers Squibb Co - Urges Shareholders To Vote "For" Proposed Celgene Transaction On White Proxy Card
Tuesday, 19 Mar 2019 06:59am EDT 

March 19 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB FILES INVESTOR PRESENTATION HIGHLIGHTING SIGNIFICANT BENEFITS OF PENDING TRANSACTION WITH CELGENE.BRISTOL-MYERS SQUIBB CO - URGES SHAREHOLDERS TO VOTE "FOR" PROPOSED CELGENE TRANSACTION ON WHITE PROXY CARD.  Full Article

Allergan PLC - Robert J. Hugin Appointed To Allergan Board Of Directors
Tuesday, 19 Feb 2019 07:00am EST 

Feb 19 (Reuters) - Allergan plc ::ROBERT J. HUGIN APPOINTED TO ALLERGAN BOARD OF DIRECTORS.ALLERGAN PLC - COMPANY TO RECOMMEND FOR A SHAREHOLDER PROPOSAL TO PHASE IN INDEPENDENT BOARD CHAIR AT NEXT LEADERSHIP TRANSITION.ALLERGAN PLC - HUGIN WAS FORMERLY CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF CELGENE CORPORATION.  Full Article

Obsidian Therapeutics Announces Strategic Collaboration With Celgene
Friday, 18 Jan 2019 07:00am EST 

Jan 18 (Reuters) - Celgene Corp ::OBSIDIAN THERAPEUTICS ANNOUNCES STRATEGIC COLLABORATION WITH CELGENE TO DEVELOP NOVEL CELL THERAPIES WITH TUNABLE IMMUNOMODULATORY FACTORS, OPENING POTENTIAL FOR CAR-T AND OTHER CELLULAR MEDICINES IN NEW SETTINGS.OBSIDIAN THERAPEUTICS SAYS COLLABORATION INCLUDES AN UPFRONT PAYMENT AND EQUITY INVESTMENT BY CELGENE.OBSIDIAN THERAPEUTICS SAYS COLLABORATION INCLUDES POTENTIAL FUTURE MILESTONE AND ROYALTY PAYMENTS BY CELGENE.OBSIDIAN THERAPEUTICS- ENTER INTO MULTI-YEAR STRATEGIC COLLABORATION WITH CELGENE RECEIVING EXCLUSIVE OPTIONS TO LICENSE CELL THERAPIES.OBSIDIAN - DEAL GIVES CELGENE EXCLUSIVE OPTION TO IN-LICENSE WORLDWIDE RIGHTS FOR CELL THERAPY CANDIDATES THAT INCORPORATE DD-REGULATED IL12 OR CD40L.  Full Article

Biond Biologics Announces $17 Mln Series B Financing
Tuesday, 8 Jan 2019 07:00am EST 

Jan 8 (Reuters) - Celgene Corp ::BIOND BIOLOGICS ANNOUNCES $17 MILLION SERIES B FINANCING.BIOND BIOLOGICS - FINANCING AND DUE DILIGENCE LED BY ISRAEL BIOTECH FUND, HAREL INSURANCE & FINANCE GROUP, WITH PARTICIPATION OF CELGENE, OTHERS.  Full Article

Nantcell Announces New Celgene Investment
Friday, 4 Jan 2019 07:01pm EST 

Jan 4 (Reuters) - Celgene Corp ::NANTCELL ANNOUNCES NEW CELGENE INVESTMENT.NANTCELL SAYS SECOND ROUND CROSSOVER FUNDING BRINGS CELGENE'S INVESTMENT TO $105M IN NANTCELL VALUED AT $4 BILLION.  Full Article

Photo

Anadarko to negotiate sale to Occidental 'superior' to Chevron deal

Anadarko Petroleum Corp said on Monday it would negotiate with Occidental Petroleum Corp over its $38 billion cash-and-stock bid, after determining it could get a better deal than its agreed $33 billion sale to Chevron Corp.